Daiichi Sankyo and AstraZeneca have received approval from China’s National Medical Products Administration (NMPA) for ...

Stealth secured a new agency review of its experimental therapy elamipretide after a rejection this year. The result could ...

The Food and Drug Administration (FDA) has granted accelerated approval to Datroway ® (datopotamab deruxtecan-dlnk) for adults with locally advanced or metastatic epidermal growth factor receptor ...

Dr. Jacob Sands discusses the significance of the FDA approval of Datroway for the treatment of patients with locally advanced or metastatic EGFR+ NSCLC.

Beginning treatment for your lung cancer often brings questions surrounding what side effects will be experienced, according to Dr. Jacob Sands.

AstraZeneca's oncology sales jump 18% in second-quarter 2025, fueled by key drugs and new launches like Truqap and Datroway.

Datopotamab deruxtecan (Dato-DXd), also known as DATROWAY, is an experimental antibody-drug conjugate (ADC) being evaluated for the treatment of triple-negative breast cancer, both as a standalone ...

Q2 2025 Earnings Call Transcript August 13, 2025 Mersana Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

Newer drugs like Wainua, Airsupra, Saphnelo, Datroway (partnered with Daiichi Sankyo) and Truqap also contributed to top-line growth in the second quarter.

Ifinatamab deruxtecan (I-DXd) has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with extensive-stage small cell ...

At ASCO in June this year, AstraZeneca presented encouraging early data from trials evaluating rilvegostomig in combination with TROP2 ADC, Datroway, in NSCLC and in combination with chemotherapy ...

Datopotamab deruxtecan (Dato-DXd), also known as DATROWAY, is an experimental antibody-drug conjugate (ADC) being evaluated for the treatment of triple-negative breast cancer, both as a standalone ...